Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

 Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Shots:                                                                                                                                               

  • Roche & Synlogic enter into a clinical collaboration to evaluate the combination therapy of Synlogic’s SYNB1891 with Roche’s Tecentriq (atezolizumab) to treat patients with advanced solid tumors
  • Synlogic plans to file an IND for SYNB1891 to the US FDA in H2’19 for the onset of P-I clinical studies evaluating SYNB1891 as monothx. and in combination with Tecentriq (atezolizumab)
  • SYNB1891 (administered intratumorally) is a non-pathogenic strain of E.coli, engineered to express a STING agonist & stimulating the innate immune system. Synlogic also developing it as a Synthetic Biotic therapy designed to act locally & providing a systemic effect in patients

Click here to read full press release/ article | Ref: Synlogic | Image: Synlogic

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post